ARS Pharmaceuticals, Inc
$ 9.97
4.40%
04 Dec - close price
- Market Cap 944,004,000 USD
- Current Price $ 9.97
- High / Low $ 10.02 / 9.44
- Stock P/E N/A
- Book Value 1.49
- EPS -0.81
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.46 %
- 52 Week High 18.90
- 52 Week Low 6.66
About
ARS Pharmaceuticals, Inc. is an innovative biopharmaceutical company based in San Diego, California, focused on developing ARS-1, an advanced intranasal epinephrine aerosol designed to provide rapid relief for individuals at risk of life-threatening allergic reactions. By leveraging proprietary absorption technology, ARS-1 aims to improve the accessibility and usability of epinephrine delivery, catering to the needs of patients and their families. The company's commitment to addressing critical public health challenges positions it as a key player in the allergy treatment market.
Analyst Target Price
$28.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-13 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-06 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-15 | 2023-03-23 |
| Reported EPS | -0.52 | -0.46 | -0.35 | 0.51 | -0.2 | -0.13 | -0.11 | -0.07 | -0.16 | -0.18 | -0.16 | 0.77 |
| Estimated EPS | -0.4581 | -0.46 | -0.11 | -0.1175 | -0.15 | -0.12 | -0.11 | -0.14 | -0.18 | -0.17 | -0.17 | -0.13 |
| Surprise | -0.0619 | 0 | -0.24 | 0.6275 | -0.05 | -0.01 | 0 | 0.07 | 0.02 | -0.01 | 0.01 | 0.9 |
| Surprise Percentage | -13.5123% | 0% | -218.1818% | 534.0426% | -33.3333% | -8.3333% | 0% | 50% | 11.1111% | -5.8824% | 5.8824% | 692.3077% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SPRY
2025-10-21 13:32:26
RA Capital Management has provided an initial $100 million investment to ARS Pharmaceuticals, Inc. to support the expansion of commercial activity for _neffy_, a nasal spray for allergic reactions. This financing is part of RA Capital's new Structured Capital strategy, which offers flexible financing solutions to innovative healthcare companies. The investment aims to accelerate the adoption of _neffy_ and leverage RA Capital's comprehensive support for its portfolio companies.
2025-10-21 13:32:26
Wilson Sonsini Goodrich & Rosati advised ARS Pharmaceuticals, Inc. on patent matters related to a senior secured term loan facility of up to $250 million. The facility, entered into with affiliates of RA Capital Management and OMERS Life Sciences, will provide an initial $100 million to accelerate the commercial growth of neffy®, ARS Pharma's nasal spray for allergic reactions. The funding will also support marketing and medical affairs initiatives for neffy.
2025-10-21 13:32:26
ARS Pharmaceuticals announced that the European Patent Office upheld the validity of all claims in a key patent related to its neffy® epinephrine nasal spray, ensuring intellectual property coverage until at least 2039. This favorable decision follows a successful defense of a similar patent challenge in the U.S., reinforcing the strength of the company's global patent portfolio for intranasal epinephrine. neffy® is an emergency treatment for allergic reactions, including anaphylaxis, in adults and children aged 4 years and older.
2025-10-21 13:32:26
ARS Pharmaceuticals is highlighted for its Neffy product, the first non-injectable epinephrine for severe allergic reactions, which presents a first-mover advantage and strong global market potential. The company targets extensive U.S. commercial coverage and international expansion with a robust financial position, including significant cash reserves and no long-term debt, supported by a lucrative licensing deal. This article provides an updated analysis of SPRY stock, emphasizing its growth prospects.
2024-12-31 00:00:00
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company with a US$1.0b market-cap, is projected to reach profitability in 2026, according to analysts, after incurring recent losses. The company's path to breakeven involves an optimistic average annual growth rate of 71%. Notably, ARS Pharmaceuticals operates without debt, reducing investment risk for a loss-making biotech.
2024-12-12 14:32:00
ARS Pharmaceuticals announced that its licensing partners have filed for approval of neffy® (epinephrine nasal spray) 2 mg in China, Japan, and Australia. This follows neffy's recent U.S. approval for treating Type I Allergic Reactions, including anaphylaxis. The company emphasized neffy's unique attributes, such as being needle-free and having a long shelf-life, which are particularly beneficial for the Asia Pacific region.
